Excess serum uric acid is associated with metabolic syndrome in obese adolescent patients

Foster, Christy; Smith, Laurie G.; Alemzadeh, Ramin

doi:10.1007/s40200-020-00507-2

Cited by 23 publications

(31 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The association of hyperuricemia with metabolic syndrome and increased cardiovascular risk was well known in the medical literature [ 2 , 51 , 52 ]. In this study, we found that 9.3% of the patients with polypharmacy were prescribed inhibitors of uric acid production in 2015, with a prevalence ratio of 1.6 compared to 2005.…”

Section: Discussionmentioning

confidence: 99%

Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data

Hernández-Rodríguez

Sempere-Verdú

Vicens

et al. 2021

IJERPH

View full text Add to dashboard Cite

We aimed to identify and compare medication profiles in populations with polypharmacy between 2005 and 2015. We conducted a cross-sectional study using information from the Computerized Database for Pharmacoepidemiologic Studies in Primary Care (BIFAP, Spain). We estimated the prevalence of therapeutic subgroups in all individuals 15 years of age and older with polypharmacy (≥5 drugs during ≥6 months) using the Anatomical Therapeutic Chemical classification system level 4, by sex and age group, for both calendar years. The most prescribed drugs were proton-pump inhibitors (PPIs), statins, antiplatelet agents, benzodiazepine derivatives, and angiotensin-converting enzyme inhibitors. The greatest increases between 2005 and 2015 were observed in PPIs, statins, other antidepressants, and β-blockers, while the prevalence of antiepileptics was almost tripled. We observed increases in psychotropic drugs in women and cardiovascular medications in men. By patient´s age groups, there were notable increases in antipsychotics, antidepressants, and antiepileptics (15–44 years); antidepressants, PPIs, and selective β-blockers (45–64 years); selective β-blockers, biguanides, PPIs, and statins (65–79 years); and in statins, selective β-blockers, and PPIs (80 years and older). Our results revealed important increases in the use of specific therapeutic subgroups, like PPIs, statins, and psychotropic drugs, highlighting opportunities to design and implement strategies to analyze such prescriptions’ appropriateness.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data

Hernández-Rodríguez

Sempere-Verdú

Vicens

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Obesity is also an important risk factor for hyperuricemia, gout, and insulin resistance, which is harmful to the development of hypertension, coronary heart disease, and diabetes mellitus [ 24 ]. The disorder of lipid metabolism is an important reason for elevation of uric acid levels caused by obesity [ 25 , 26 ]. Akkermansia muciniphila , a kind of intestinal anaerobes, mainly grows in the intestinal mucinous layer of mammals [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Effect of a Traditional Chinese Medicine Formula (CoTOL) on Serum Uric Acid and Intestinal Flora in Obese Hyperuricemic Mice Inoculated with Intestinal Bacteria

Gao

Sun

Zhang

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

CoTOL is a traditional Chinese medicine (TCM) formula in clinics for treating gout and hyperuricemia, especially in obese patients with recurrent attacks. However, fewer studies have investigated how CoTOL impacts the intestinal flora in reducing uric acid. In the present, we analyze the bacteria targeted by ingredients of CoTOL and evaluate the effects of CoTOL on uric acid and intestinal flora in a mice model of obese hyperuricemia inoculated with xanthine dehydrogenase- (XOD-) producing bacteria, Streptococcus faecalis. Firstly, ingredients of herbs in CoTOL and gene target by these ingredients were retrieved from TCMID 2.0, and these genes were screened by DAVID Bioinformatics Resources 6.8, deciphered to retrieve the bacteria. Then, 3-4-week-old male C57bl/6j mice were randomly divided into 6 groups and fed with high fat diet for 8 weeks up to obesity standard. The mice were inoculated intragastrically with 5 × 109 CFU Streptococcus faecalis 3 times at the 5th, 6th, and 7th week and intragastrically administrated with uricase inhibitor, potassium-oxonate (PO, 250 mg/kg), to induce hyperuricemia at the 8th week, once a day for 7 consecutive days, respectively (IB model). IB model plus CoTOL (0.4 ml/20g) and allopurinol (40 mg/kg) were administrated by gavage at the 5th week, once a day for 4 weeks. The feces and blood in each group were sampled at the 4th and 8th week. With no bacteria inoculation, CoTOL, allopurinol, and blank group were treated with CoTOL and allopurinol or water, respectively. 44 species of bacteria (i.e., Enterococcus faecalis, Streptococcus, etc.) genes were targeted by 6 ingredients of 6 herbs in CoTOL. Inoculation with Streptococcus faecalis significantly caused the elevation of uric acid and the change of intestinal flora structure, whereas treatment with CoTOL signiﬁcantly increased the abundance of Akkermansia and those of Bacteroides and Alloprevotella decreased. Furthermore, CoTOL exhibited a unique effect on reducing weight unobserved in allopurinol intervention. The present study, for the first time, demonstrated that CoTOL has beneficial effects on hyperuricemia and overweight, which may be attributed to regulating material metabolism and improving the structure or function of intestinal flora. Thus, CoTOL may be a promising therapy for hyperuricemia and overweight in chronic gout management and can be integrated with conventional treatments.

show abstract

“…Uric acid is the end product of purine metabolism and is secreted by the kidney [1]. Elevated levels of serum uric acid level (SUA) can result from decreased renal clearance [1]. Hyperuricemia is an abnormal condition with higher level of uric acid in the blood [2].…”

Section: Introductionmentioning

confidence: 99%

“…Hyperuricemia is an abnormal condition with higher level of uric acid in the blood [2]. Hyperuricemia is due to an imbalance of increased production of uric acid or/and decreased excretion of uric acid, which may result in serious complications including gout, tophi, kidney stones, or urate nephropathy even kidney failure [1,2] . In human, if the concentration of SUA reaches to 357 μmol/l (6 mg/dl) for women and 416 μmol/l (7.0 mg/dl) for men, hyperuricemia could be diagnosed [2].…”

Section: Introductionmentioning

confidence: 99%

“…Pro inflammatory properties of uric acid, accounting for this atherogenic potential, include a positive correlation of its concentration with increased levels of inflammatory markers, such as high-sensitivity Creactive protein (hs-CRP), interleukin-6, tumor necrosis factor α (TNF α) as well as of chemoattractant and adhesion molecules [4]. High levels of SUA will lead to sequelae including hypertension hypertriglyceridemia, and hypercholesterolemia [1]. Also, hyperuricemia has been associated with an increased risk for early death in patients with an acute stroke [1].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Orlistat on serum Uric acid level in adults: A systematic review and meta-analysis of randomized controlled trials

Noori¹,

Mirzababaei²,

Mirzaei³

2020

Preprint

View full text Add to dashboard Cite

Objective: Hyperuricemia increases the risk of gout and cardiovascular diseases. Obesity increase the risk of hyperuricemia while weight loss (>5 kg) has been reported to decrease urate. The effects of orlistat on serum uric acid is still controversial. The aim of this meta-analysis was to evaluate the influence of orlistat on serum uric acid level in adults. Methods: Relevant studies, published up to May 2020, were searched systematically through PubMed/Medline, Scopus, and Google Scholar. All relevant randomized controlled clinical trials were included. Meta-analysis was performed using random-effect model. Subgroup analysis, sensitivity analysis, and meta-regression were also carried out Results: Overall 7 trials (9 dataset) that enrolled 1786 subjects were included. Orlistat showed in significant change in serum uric acid level (Difference in means: -17.661μmol, 95% CI: -31.615 to -3.707, P=0.01). A low heterogeneity observed across the studies (Iˆ2 = 25.119%). After categorizing studies on the basis of duration and sample size the effect of orlistat on serum uric acid was significant. The results of meta-regression were showed that significant relationships were not found between orlistat and serum uric acid in duration of intervention. Conclusion: We found a significant reduction in serum uric acid following orlistat therapy in adults.

show abstract

Excess serum uric acid is associated with metabolic syndrome in obese adolescent patients

Cited by 23 publications

References 50 publications

Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data

Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data

Effect of a Traditional Chinese Medicine Formula (CoTOL) on Serum Uric Acid and Intestinal Flora in Obese Hyperuricemic Mice Inoculated with Intestinal Bacteria

Effect of Orlistat on serum Uric acid level in adults: A systematic review and meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About